

PRESS RELEASE
26 August 2022 10:15:00 CEST



ProstaLund signs distribution agreement for Brazil

ProstaLund AB has signed an exclusive distribution agreement with the Brazilian company Gadali Medical Comercio de Produtos Medico Hospitalar Ltda. The agreement enters into force as soon as the registration of the products is completed with the Brazilian authorities. The agreement is expected to generate revenue of at least SEK 2 million during the first two years of the agreement period.

Earlier this year, ProstaLund began internationalization outside the Nordic region and has signed distribution agreements for the UK and Israel. Now the next step in this process is taken as a distribution agreement has been signed for Brazil with Gadali Medical.

Gadali Medical Comercio de Produtos Medico Hospitalar Ltda is a leading Brazilian company for the marketing of medical technology and has, among other things, a broad urological product portfolio and thus a wide network of urologists in the country.

The agreement with Gadali includes CoreFlow® - Soft Stent and the Schelin® Catheter. The registration process started earlier this summer after Gadali, together with leading urologists in Brazil, evaluated the products. Registration is not yet finalized but is expected to be completed within a couple of months. The products will be presented at Latin America's largest urology congress, XVII Congresso Paulista de Urologia in São Paulo, on September 3-6 this year.

"The interest in our stand-alone products CoreFlow® - Soft Stent and the Schelin® Catheter is very great far beyond the Nordic region. It will be exciting to follow our entry into South America's largest market", says CEO Johan Wennerholm in a comment.

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
26 August 2022 10:15:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-08-26 10:15 CEST.

Attachments

ProstaLund signs distribution agreement for Brazil